biote Corp.BTMDEarnings & Financial Report
biote Corp is a healthcare company specializing in personalized bioidentical hormone replacement therapy solutions for adult men and women. It operates primarily in the U.S. market, offering training programs for licensed healthcare providers, along with complementary wellness supplements and diagnostic services to support patient care outcomes.
BTMD Q4 FY2025 Key Financial Metrics
Revenue
$46.4M
Gross Profit
N/A
Operating Profit
$6.8M
Net Profit
$2.0M
Gross Margin
N/A
Operating Margin
14.7%
Net Margin
4.2%
YoY Growth
-6.9%
EPS
$0.05
biote Corp. Q4 FY2025 Financial Summary
biote Corp. reported revenue of $46.4M (down 6.9% YoY) for Q4 FY2025, with a net profit of $2.0M (down 47.2% YoY) (4.2% margin).
Key Financial Metrics
| Total Revenue | $46.4M |
|---|---|
| Net Profit | $2.0M |
| Gross Margin | N/A |
| Operating Margin | 14.7% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
biote Corp. Q4 FY2025 revenue of $46.4M breaks down across 2 segments, led by Product Revenue at $45.3M (97.6% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Product Revenue | $45.3M | 97.6% |
| Disposable Trocars Product Revenue | $1.2M | 2.6% |
biote Corp. Revenue by Segment — Quarterly Trend
biote Corp. revenue by segment across the last 4 reported quarters, showing how each business line (such as Product Revenue and Disposable Trocars Product Revenue) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Product Revenue | $45.3M | $47.0M | $47.7M | — |
| Disposable Trocars Product Revenue | $1.2M | $1.2M | $1.2M | $1.2M |
biote Corp. Annual Revenue by Year
biote Corp. annual revenue history includes year-by-year totals (for example, 2025 revenue was $192.2M).
biote Corp. Quarterly Revenue & Net Profit History
biote Corp. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $46.4M | -6.9% | $2.0M | 4.2% |
| Q3 FY2025 | $48.0M | -6.7% | $8.2M | 17.1% |
| Q2 FY2025 | $48.9M | -0.6% | $3.2M | 6.5% |
| Q1 FY2025 | $49.0M | +4.7% | $13.7M | 28.0% |
| Q4 FY2024 | $49.8M | +9.0% | $3.7M | 7.4% |
| Q3 FY2024 | $51.4M | +12.8% | $10.7M | 20.8% |
| Q2 FY2024 | $49.2M | -0.2% | $-7.1M | -14.4% |
| Q1 FY2024 | $46.8M | +4.4% | $-4.2M | -8.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $46.8M | $49.2M | $51.4M | $49.8M | $49.0M | $48.9M | $48.0M | $46.4M |
| YoY Growth | 4.4% | -0.2% | 12.8% | 9.0% | 4.7% | -0.6% | -6.7% | -6.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $160.1M | $92.9M | $101.3M | $122.4M | $123.4M | $104.8M | $111.3M | $107.6M |
| Liabilities | $205.0M | $234.6M | $228.1M | $224.6M | $208.2M | $183.6M | $176.8M | $158.0M |
| Equity | $-36.0M | $-143.2M | $-130.3M | $-105.9M | $-90.0M | $-85.1M | $-72.8M | $-58.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $7.4M | $9.9M | $15.6M | $12.4M | $6.5M | $7.1M | $14.1M | $7.6M |